173 related articles for article (PubMed ID: 35049189)
1. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Xiao BY; Wang BC; Lin GH; Li PC
Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Herrmann R; Bodoky G; Ruhstaller T; Glimelius B; Bajetta E; Schüller J; Saletti P; Bauer J; Figer A; Pestalozzi B; Köhne CH; Mingrone W; Stemmer SM; Tàmas K; Kornek GV; Koeberle D; Cina S; Bernhard J; Dietrich D; Scheithauer W; ;
J Clin Oncol; 2007 Jun; 25(16):2212-7. PubMed ID: 17538165
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
Li Q; Yuan Z; Yan H; Wen Z; Zhang R; Cao B
Clin Ther; 2014 Jul; 36(7):1054-63. PubMed ID: 24986485
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
13. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
Huan L; Yu F; Cao D; Zhou H; Qin M; Cao Y
PLoS One; 2024; 19(3):e0295983. PubMed ID: 38451955
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
[TBL] [Abstract][Full Text] [Related]
18. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Xie DR; Yang Q; Chen DL; Jiang ZM; Bi ZF; Ma W; Zhang YD
Jpn J Clin Oncol; 2010 May; 40(5):432-41. PubMed ID: 20147334
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
